



Co-funded by the European Union
Grant Agreement n° 874719

Congenica L3/ L4

(Lead: Congenica Limited BIC Wellcome Genome Campus)



Project abstract

Congenica will build a system to meet the requirements as laid out by Lots 3 and 4 of the program as contributing components toward an end-to-end system designed to improve patient outcomes and clinical workflows.

For Lot 3 Congenica will deliver a fully automated secondary pipeline that will be able to call variants and automatically classify variants as pathogenic or benign and pass the results onto the Lot 4 system for the next stage in the process. It will be built to be integrated with the required touchpoints within the full workflow & is flexible enough to align with disease specific requirements, differing sample types & SOPs.

For Lot 4 Congenica will deliver an automated reporting application that provides therapy guidance for a patient in relation to their specific circumstances. Optional multi-user approval checks will be included to ensure reporting accuracy and consistency, while manual reporting will also be available for complex cases.